Cencora, Inc. $COR Shares Newly Acquired by Machina Capital S.A.S.

Machina Capital S.A.S. bought a new stake in shares of Cencora, Inc. (NYSE:COR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 8,942 shares of the company’s stock, valued at approximately $2,685,000.

Several other institutional investors also recently bought and sold shares of the company. Lido Advisors LLC increased its stake in Cencora by 8.9% during the 3rd quarter. Lido Advisors LLC now owns 8,760 shares of the company’s stock worth $2,630,000 after buying an additional 715 shares during the period. Keybank National Association OH lifted its holdings in Cencora by 3.6% during the 3rd quarter. Keybank National Association OH now owns 18,206 shares of the company’s stock worth $5,466,000 after buying an additional 630 shares in the last quarter. D Orazio & Associates Inc. acquired a new stake in Cencora during the 3rd quarter worth approximately $206,000. 71 West Capital Partners boosted its position in Cencora by 5.6% in the 3rd quarter. 71 West Capital Partners now owns 1,805 shares of the company’s stock valued at $542,000 after buying an additional 95 shares during the period. Finally, Beutel Goodman & Co Ltd. boosted its position in Cencora by 29.1% in the 3rd quarter. Beutel Goodman & Co Ltd. now owns 658,222 shares of the company’s stock valued at $197,631,000 after buying an additional 148,544 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Up 0.4%

COR stock opened at $349.96 on Thursday. The company’s 50 day moving average price is $326.43 and its 200 day moving average price is $317.22. The company has a debt-to-equity ratio of 3.01, a quick ratio of 0.59 and a current ratio of 0.94. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The firm has a market capitalization of $66.78 billion, a price-to-earnings ratio of 19.53, a PEG ratio of 1.80 and a beta of 0.58.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.58 by $0.08. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The company had revenue of $88.35 billion during the quarter, compared to the consensus estimate of $87.95 billion. During the same quarter in the previous year, the firm earned $3.84 earnings per share. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. On average, equities research analysts anticipate that Cencora, Inc. will post 19.58 EPS for the current fiscal year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Stockholders of record on Friday, November 13th will be issued a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, November 13th. This is a positive change from Cencora’s previous quarterly dividend of $0.60. Cencora’s dividend payout ratio (DPR) is 14.73%.

Wall Street Analyst Weigh In

Several equities analysts have commented on COR shares. Leerink Partners boosted their price target on shares of Cencora from $388.00 to $405.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Bank of America increased their price objective on Cencora from $285.00 to $310.00 in a research note on Tuesday, July 21st. Evercore reiterated an “outperform” rating and issued a $350.00 price objective (up from $330.00) on shares of Cencora in a research note on Thursday, August 6th. Wells Fargo & Company lifted their target price on Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Finally, Morgan Stanley lifted their target price on Cencora from $346.00 to $377.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Twelve equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $368.14.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction on Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. The trade was a 36.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.38% of the company’s stock.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.